On Wednesday, Aug. 7, The centers for Medicare & Medicaid Services (CMS) approved CAR T therapy, which uses a patient’s own genetically-modified immune cells to fight specific types of cancer: non-Hodgkin lymphoma and B-cell precursor acute lymphoblastic leukemia.
In addition, Medicare will cover FDA-approved CAR T therapies...
